Ginkgo Bioworks Holdings Inc. Class A (DNA)

$8.02

up-down-arrow $0.18 (2.30%)

As on 28-Apr-2025 16:10EDT

Ginkgo Bioworks Holdings Inc. Class A (DNA) Share Price

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 7.77 High: 8.40

52 Week Range

Low: 5.00 High: 45.20

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Market capMarket cap information

    $457 Mln

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    0.64

  • Industry P/EIndustry P/E information

    --

  • Debt to EquityDebt to Equity information

    0.61

  • ROEROE information

    -0.6 %

  • ROCEROCE information

    -43.87 %

  • Div. YieldDiv. Yield information

    0 %

  • Book ValueBook Value information

    13.8

  • EPSEPS information

    -10.54

5 Years Aggregate

CFO

$-982.01 Mln

EBITDA

$-4,847.20 Mln

Net Profit

$-5,082.46 Mln

Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Ginkgo Bioworks Holdings Inc. Class A (DNA)
-18.33 21.70 -32.15 -76.69 -61.19 -- --
BSE Sensex*
2.59 3.69 5.76 8.88 11.75 20.11 11.35
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 28-Apr-2025  |  *As on 29-Apr-2025  |  #As on 26-Oct-2023
2024
2023
2022
Ginkgo Bioworks Holdings Inc. Class A (DNA)
-85.24 0.00 -79.66
S&P Small-Cap 600
7.01 13.89 -17.42
BSE Sensex
8.10 18.74 4.44

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

Detailed View
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View All
loading...

loading...

loading...

3Y Avg -- 5Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peer

View All
Company
Price ($) Market Cap ($ Mln) P/E Ratio ROE
38.44 10,315.11 21.27 23.13
298.18 8,705.27 22.77 66.44
27.46 10,589.59 -- -28.77
106.46 10,559.67 32.44 14.16

Shareholding Pattern

Detailed Holdings
loading...
BLAHBLAH

About The Company

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development...  solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 27 Drydock Avenue, Boston, MA, United States, 02210  Read more

  • Founder, CEO & Director

    Dr. Jason Kelly

  • Founder

    Mr. Thomas Knight Jr.

  • Headquarters

    Boston, MA

  • Website

    https://www.ginkgo.bio

Edit peer-selector-edit
loading...
loading...

FAQs for Ginkgo Bioworks Holdings Inc. Class A (DNA)

The total asset value of Ginkgo Bioworks Holdings Inc Class A (DNA) stood at $ 1,377 Mln as on 31-Dec-24

The share price of Ginkgo Bioworks Holdings Inc Class A (DNA) is $8.02 (NYSE) as of 28-Apr-2025 16:10 EDT. Ginkgo Bioworks Holdings Inc Class A (DNA) has given a return of -61.19% in the last 3 years.

Ginkgo Bioworks Holdings Inc Class A (DNA) has a market capitalisation of $ 457 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.

Since, TTM earnings of Ginkgo Bioworks Holdings Inc Class A (DNA) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ginkgo Bioworks Holdings Inc Class A (DNA) and enter the required number of quantities and click on buy to purchase the shares of Ginkgo Bioworks Holdings Inc Class A (DNA).

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 27 Drydock Avenue, Boston, MA, United States, 02210

The CEO & director of Dr. Jason Kelly. is Ginkgo Bioworks Holdings Inc Class A (DNA), and CFO & Sr. VP is Mr. Thomas Knight Jr..

There is no promoter pledging in Ginkgo Bioworks Holdings Inc Class A (DNA).

Ginkgo Bioworks Holdings Inc. Class A (DNA) Ratios
Return on equity(%)
-60.34
Operating margin(%)
-241.11
Net Margin(%)
-240.94
Dividend yield(%)
--

No, TTM profit after tax of Ginkgo Bioworks Holdings Inc Class A (DNA) was $0 Mln.